The back-step method - Method for obtaining unbiased population parameter estimates for ordered categorical data

AAPS Journal

Volumn 6, Issue 3, 2004, Pages

  Kjellsson, Maria C ^a   Jönsson, Siv ^a   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Bias in parameter estimates; Laplacian; NONMEM; Ordered categorical; Pharmacodynamics; Proportional odds model

Indexed keywords

ACCURACY; ANALYSIS OF VARIANCE; ANALYTIC METHOD; ARTICLE; COMPUTER PROGRAM; COMPUTER SIMULATION; CONTROLLED STUDY; DATA ANALYSIS; INFORMATION PROCESSING; INTERMETHOD COMPARISON; POPULATION RESEARCH; PREDICTION; EPIDEMIOLOGY; MONTE CARLO METHOD; PHARMACOKINETICS; STATISTICAL MODEL;

BIAS (EPIDEMIOLOGY); MODELS, STATISTICAL; MONTE CARLO METHOD; PHARMACOKINETICS; SOFTWARE;

EID: 33646667317     PISSN: 15221059     EISSN: 15221059     Source Type: Journal    
DOI: 10.1208/aapsj060319     Document Type: Article

References (22)

1. SL Beal, LB Sheiner. NONMEM users guides (I-VIII). Hanover, Maryland: GloboMax: 1989-1998.
2. White DB, Walawander CA, Tung Y, et al. An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis. J Pharmacokinet Biopharm. 1991;19:87-112.
3. Bennett JE, Wakefield JC. A comparison of a Bayesian population method with two methods as implemented in commercially available software. J Pharmacokinet Biopharm. 1996;24:403-432.
4. Wakefield J, Walker S. A population approach to initial dose selection. Stat Med. 1997;16:1135-1149.
5. EN Jonsson, JR Wade, MO Karlsson. Nonlinearity detection: advantages of nonlinear mixed-effects modeling. AAPS PharmSci. 2000;2(3):E32. Available from: http://www.aapspharmsci.org/.
6. Gupta SK, Sathyan G, Lindemulder EA, et al. Quantitative characterization of therapeutic index: Application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. Clin Pharmacol Ther. 1999;65:672-684.
7. Mandema JW, Stanski DR. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther. 1996;60:619-635.
8. Mould DR, Holford NH, Schellens JH, et al. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther. 2002;71:334-348.
9. Sheiner LB. A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data. Clin Pharmacol Ther. 1994;56:309-322.
10. Jönsson S. Estimation of dosing strategies for individualisation [dissertation]. Uppsala, Sweden: Acta Universitatis Upsaliensis; 2004. Available at: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4255.
11. Kowalski KG, McFadyen L, Hutmatcher MM, et al. A Two-Part Mixture Model for Longitudinal Adverse Event Severity Data. J Pharmacokinet Pharmacodyn. 2003;30:315-336.
12. Olsen MK, Schafer JL. A Two-Part Random-Effects Model for Semicontinuous Longitudinal Data. J Am Stat Assoc. 2001;96:730-745.
13. Hietaniemi J. Comprehensive Perl Archive Network. http://www.cpan.org (October 2003).
14. Gelman A, Carlin JB, Stern HS, et al. Bayesian data analysis. London, UK: Chapman & Hall; 1995.
15. Girard P, Blaschke TF, Kastrissios H, et al. A Markov mixed effect regression model for drug compliance. Stat Med. 1998;17:2313-2333.
16. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001;28:171-192.
17. Beal SL. Commentary on significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2002;29:403-410;discussion 411-412.
18. Gisleskog PO, Karlsson MO, Beal SL. Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn. 2002;29:473-505.
19. Karlsson MO, Jonsson EN, Wiltse CG, et al. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm. 1998;26:207-246.
20. Efron B. Better Bootstrap Confidence Intervals. J Am Stat Assoc. 1987;82:171-185.
21. Yano I, Beal SL, Sheiner LB. The Need For Mixed-Effects Modeling with Population Dichotomous Data. J Pharmacokinet Pharmacodyn. 2001;28:389-412.
22. Wählby U, Jonsson EN, Karlsson MO. Assessment of Actual Significance Levels for Covariate Effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001;28:231-252.